Stocks · News reference
Centene beat Q2 earnings and revenue estimates, raised its 2026 outlook, improved medical cost trends, and reported lower Medicaid membership.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
IQVIA (IQV) has surged 60.1% over six months, driven by 6% organic growth in Q2 2026, with R&DS bookings up 19.3% and a $34.2 billion backlog. The company's rapid AI adoption—294 agents deployed across 90 use cases with 19 of top 20 pharma companies adopting solutions—is strengthening its competitive position and supporting sustained growth.
The Invesco S&P 500 Pure Value ETF (RPV) is a smart beta ETF with $1.75 billion in assets that tracks the S&P 500 Pure Value Index. It has delivered 19.31% year-to-date returns and 26.47% over the past year with a 0.35% expense ratio. The fund holds 125 stocks with heavy exposure to Financials (20.4%), Healthcare, and Consumer Staples sectors. While RPV offers reasonable value-focused exposure, cheaper alternatives like Vanguard's VTV (0.03% expense ratio) and Schwab's SCHD (0.06% expense ratio) may be more cost-effective for investors.
Centene (NYSE:CNC) FY2026 expected to be more than $3.11 vs $2.47 Est..
September 16, 2026, at 9:00 a.m. EDT. During the conference, and in subsequent discussions with investors continuing through the week of September 21, members of management will discuss the Company's business and
U.S. stocks fell, but Wealthfront surged 6.6% after beating Q2 earnings and revenue estimates; Orchestra Biomed, Clover Health and AeroVironment also rose.